Skip to main content
Premium Trial:

Request an Annual Quote

Oxford BioDynamics to Raise £12.0M in Stock Placement, Offering

NEW YORK — Oxford BioDynamics said on Friday that it has conditionally secured £9.1 million ($10.1 million) through the private placement of roughly 45.1 million newly issued shares of common stock at 20 pence apiece to institutional and other investors.

The Oxford, UK-based diagnostics firm also said that it is planning to offer shareholders up to about 14.7 million additional newly issued ordinary shares at 20 pence each, which would raise approximately £2.9 million.

Both the placement and the offering are subject to shareholder approval.

During afternoon trading on the London Stock Exchange's AIM, shares of Oxford BioDynamics were up nearly 23 percent at 18.39 pence per share.

Oxford BioDynamics intends to use the funds to accelerate commercialization of its EpiSwitch technology for the detection of chromosome conformation signature biomarkers, including the newly launched EpiSwitch CiRT blood test for predicting patient response to immune checkpoint inhibitors.

The company said it will also use the money to continue developing its pipeline of molecular diagnostic tests in the US and other markets, conduct proprietary research, and maintain and develop its broad intellectual property portfolio.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.